Clinical trials: Diabetes type2
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented.
- Trial name
- NCT03603704
- Testing
- LY3209590
- Where
- 3 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
- Trial name
- NCT00306384
- Testing
- Alogliptin
- Where
- 114 sites in United States, Argentina and 10 more
- Volunteers
- 3,323 people
- Sponsor
- Takeda
Diabetic Kidney Disease, Chronic Kidney Diseases
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- NCT05198284
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Type 2 Diabetes Mellitus
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
This is a prospective, interventional, single arm, multicenter, phase 4 study to evaluate the clinical efficacy and safety of initiating Insulin glargine U300 in insulin-naive patients or switching from any other basal insulin to…
- Trial name
- INITIATION (NCT05002933)
- Testing
- Insulin glargine 300 U/ml
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sanofi
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes…
- Trial name
- NCT03060538
- Testing
- BFKB8488A
- Where
- 18 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Genentech, Inc.
Glycemic Control
Evaluation of Glycemic Response in Individuals With Type 2 Diabetes
This is a randomized, controlled, crossover study to compare the effects to two treatments on postprandial glucose in adults with type 2 diabetes.
- Trial name
- NCT05165693
- Testing
- Experimental Formula, Test Meal
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Abbott Nutrition
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Chronic Kidney Diseases, Diabetic Kidney Disease
Real World Evidence Clinical Utility Study of KidneyIntelX
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
- Trial name
- NCT04802395
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Renalytix AI, Inc.
Type 2 Diabetes, Diabetes Mellitus Type 2
AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes
AIM-MET is a randomized clinical study testing whether a fixed microbiome-targeted nutritional product can improve blood sugar control in adults with type 2 diabetes when used in addition to usual stable diabetes treatment.
- Trial name
- AIM-MET (NCT07622628)
- Testing
- Microbiome-targeted oral food supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- ENBIOSIS BIOTECHNOLOGIES
Non-Insulin-Dependent Diabetes Mellitus
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.
- Trial name
- NCT00359112
- Testing
- metformin, sulphonylurea, Avandamet
- Where
- 142 sites in Belgium, France and 9 more
- Volunteers
- 544 people
- Sponsor
- GlaxoSmithKline
Hyperglycaemia (Diabetic), Type 2 Diabetes Mellitus
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus
This is a phase I placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of Globalagliatin Hydrochloride (SY-004) after Multiple Ascending Doses in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT03414892
- Testing
- Globalagliatin Hydrochloride
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Yabao Pharmaceutical Group
Diabetes Mellitus, Type 2
US Inhaled Insulin Therapeutic Choice Questionnaire Study
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in…
- Trial name
- NCT00139763
- Testing
- Educational Materials
- Where
- 42 sites in United States
- Volunteers
- 740 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible.
- Trial name
- NCT00300287
- Testing
- Vildagliptin
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Primary Objective: The primary objective of this study was to assess the dose-response relationship of SAR425899 versus placebo in terms of glycemic control as measured by the change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT02973321
- Testing
- SAR425899, Liraglutide, Metformin
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Type 2 Diabetes
Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
This clinical study aims to evaluate the effects of using the "WellCheck" mobile application on blood glucose, blood pressure, and weight among Type 2 diabetes patients in real primary care settings.
- Trial name
- NCT06419816
- Testing
- Physician-managed "WellCheck" use, self-managed "WellCheck" use
- Where
- South Korea
- Volunteers
- 471 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus
BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance
The study is designed to compare meal time glucose control associated with BIOD-531, a rapidly absorbed concentrated insulin to that associated with Humalog Mix 75/25 and Humulin R U-500 in patients with diabetes and severe…
- Trial name
- NCT02324309
- Testing
- BIOD-531, Humalog Mix 75/25, Humulin R U-500
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Biodel
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.